HTA34 Quo Vadis Benefit Assessment for Orphan Drugs in Germany: The End of the Exception?
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.1494
https://www.valueinhealthjournal.com/article/S1098-3015(22)03699-3/fulltext
Section Title :
Section Order :
11042
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03699-3&doi=10.1016/j.jval.2022.09.1494